Medical/Pharmaceuticals
Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase
TOKYO, Feb. 22, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity...
2023-02-22 21:05
2287
CRT 2023 selects Syntach Cardiac Support System for Best Innovation Competition
LUND, Sweden, Feb. 22, 2023 /PRNewswire/ -- Syntach AB ("Syntach") is pleased to announce that the Company's Syntach Cardiac Support system (Syntach CS) has been selected for an oral presentation in the Best Innovation Competition to be held during the CRT 2023 annual meeting taking place at the ...
2023-02-22 20:22
2010
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
– Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication – NEWTON, Mass. and FLORENCE, Italy, Feb. 21, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, an...
2023-02-21 23:04
2705
New Study Shows GlycoMark® Test Identifies Prediabetic Individuals with the Highest Risk of Developing Diabetes Before Symptoms Develop
RALEIGH, N.C., Feb. 21, 2023 /PRNewswire/ -- A new study indicates that the GlycoMark blood test identifies high-risk, asymptomatic patients with prediabetes, not detected by standard diabetes tests, hemoglobin A1C and glucose – a critical clinical need, as physicians can identify those patients...
2023-02-21 20:30
1787
Organizational-level, Unified and Vendor-neutral Enterprise Imaging and Informatics Drive Effective Digital Transformation
Scalable enterprise-level solutions leverage all data at an enterprise level and can engage with the entire unified longitudinal patient record SAN ANTONIO, Feb. 21, 2023 /PRNewswire/ -- Medical imaging and healthcare digitalization have seen significant advances and evolution in recent years. T...
2023-02-21 16:12
1815
Synbio Tech Inc. and Cosmax Group signed an exclusive cooperation agreement to jointly expand the South Korean probiotics market
KAOHSIUNG, Taiwan, Feb. 21, 2023 /PRNewswire/ -- Synbio Tech Inc. and Cosmax NBT, a major South Korean biotechnology company officially signed an exclusive cooperation agreement to launchLactobacillus plantarum TWK10® probiotic strain inSouth Korea, and announced that TWK10® has been approved as ...
2023-02-21 16:01
2318
Nippon Express Singapore Receives IATA CEIV Pharma Certification for Changi International Airport Facility
TOKYO, Feb. 21, 2023 /PRNewswire/ -- Nippon Express (Singapore) Pte. Ltd. (hereinafter "NX Singapore"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired IATA CEIV Pharma (*) certification for its facility in the Free Trade Zone (FTZ) at Singapore Changi International Airport, effect...
2023-02-21 14:00
1996
Pharming announces first patient enrolled in pediatric clinical trial of leniolisib
The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands, Feb. 21, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces t...
2023-02-21 14:00
2970
Chrysalis Advisory and TriNetX Establish a Strategic Collaboration to Support Research Teams Across Australia and New Zealand
CAMBRIDGE, Mass., Feb. 21, 2023 /PRNewswire/ -- TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced a strategic collaboration with Chrysalis Advisory, also known as Chrysalis Health Group,Australia's s...
2023-02-21 13:00
1880
Ascletis Presented Positive Phase I Clinical Data for Broad-Spectrum Antiviral Double Prodrug ASC10 at CROI 2023
--At the dosage of 800 mg ASC10, twice daily (BID), the exposure of the active drug, ASC10-A, is comparable to that of monupiravir's --ASC10 at 800 mg, BID is safe and well tolerated --Dosage of 800 mg ASC10, BID was selected for Phase IIa clinical trial for respiratory syncytial virus (RSV) inf...
2023-02-21 08:10
2398
iGene Laboratory Announces Launch of Whole Exome Sequencing Service
SINGAPORE, Feb. 21, 2023 /PRNewswire/ -- Singapore-based molecular diagnostics lab group iGene Laboratory announces the launch of FetalExome test service. FetalExome test is a whole exome sequencing (WES) test available for women with potentially complicated pregnancies. The test examines and a...
2023-02-21 08:00
2009
Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma
CHENGDU, China, Feb. 20, 2023 /PRNewswire/ -- Recently, with the support of the National Key R&D Program ofChina, following the clinical trial approval for Recombinant Variant COVID-19 Vaccine (Sf9 cell) approved by NMPA, WestVac Biopharma (Guangzhou) Co., Ltd. (hereinafter referred to as "WestVa...
2023-02-20 12:43
3195
Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become a new clinical standard in the identification and characterisation of clear cell renal cell carcinoma (ccRCC): * Primary endpoint met: Sensitivi...
2023-02-20 07:10
2218
Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer
SINGAPORE, Feb. 17, 2023 /PRNewswire/ -- February 16th, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") was granted approval by US FDA for the company's IND application for BRG01 cell therapy, path the way for Phase I/II clinical trial. BRG01 is an autologous T cell therapy for relapsed/meta...
2023-02-17 23:13
7427
Farrer Park Hospital launches clinical collaboration with ARC Hospitals
SINGAPORE, Feb. 17, 2023 /PRNewswire/ -- Farrer Park Hospital (FPH) has launched a clinical collaboration with Allegiant Regional Care (ARC) Hospitals to promote continuing medical education among specialists and physicians. The collaboration was officially launched at a joint surgical conference...
2023-02-17 20:38
2878
/C O R R E C T I O N -- DoctorOnCall/
In the news release, NCSM & DoctorOnCall Join Forces to Promote Free COVID-19 Vaccination and Booster Doses (Including On-site and House-to-House), issued 12-Feb-2023 by DoctorOnCall over PR Newswire, we are advised by the company that the 7th paragraph, 1st sentence, should read "For more informa...
2023-02-17 08:00
3677
Dalton Announces Major Expansion in Commercial Sterile Manufacturing Capacity
TORONTO, Feb. 17, 2023 /PRNewswire/ -- Dalton Pharma Services today announced a major strategic expansion of its sterile filling and pharmaceutical manufacturing capacity. The capital expansion plan includes a new state-of-the-art, fully automated cGMP sterile filling line with the flexibility t...
2023-02-17 01:37
4240
Immuno Cure kick off Phase I Clinical Trial in Shenzhen
A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS HONG KONG, Feb. 16, 2023 /PRNewswire/ -- Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in PD-1-Enhanced DNA vaccines and immunotherapies,announced the ...
2023-02-16 20:36
4676
Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B
HANGZHOU and SHAOXING, China, Feb. 16, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces that the oral presentation at the 2023 annual meeting of the Asian Pacific Association for the Study of the Liver ("APASL Annual Meeting 2023") demonstrates that ASC22 (Envafol...
2023-02-16 17:10
2818
Aqilion announces pre-clinical licensing and strategic research collaboration agreement with Merck
HELSINGBORG, Sweden, Feb. 16, 2023 /PRNewswire/ -- AQILION AB ("Aqilion") today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. Me...
2023-02-16 15:00
1772
Week's Top Stories
Most Reposted
MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship
[Picked up by 331 media titles]
2024-05-23 10:00
SINGAPORE'S XSQUARE TECHNOLOGIES SECURES S$10.5M IN SERIES A FUNDING LED BY WAVEMAKER PARTNERS
[Picked up by 326 media titles]
2024-05-23 10:00Unlock the Future of Innovation: Taiwan's Premier Hardware Expo Hits the Global Stage This October
[Picked up by 314 media titles]
2024-05-24 09:41
Ultima Markets partnered with Willis Towers Watson (WTW) to offer US$1 million in fund insurance
[Picked up by 303 media titles]
2024-05-24 12:00
Elitery Named Google Cloud Managed Services Provider in Indonesia
[Picked up by 302 media titles]
2024-05-22 17:34
Most Read
MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship
2024-05-23 10:00
11534
Revolutionising Cardiac Care at Pantai Hospital Kuala Lumpur
2024-05-23 11:22
10527
